%0 Journal Article
%T FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatinİ\Containing Chemotherapy
%A Amna Ibrahim
%A Amy E. McKee
%A Daniel L. Suzman
%A Jason Schroeder
%A Julia A. Beaver
%A Kirsten B. Goldberg
%A Laura L. Fernandes
%A Rajeshwari Sridhara
%A Richard Pazdur
%A Shenghui Tang
%A Stella Karuri
%A Sundeep Agrawal
%A V. Ellen Maher
%A Yangİ\min Ning
%J Archive of "The Oncologist".
%D 2019
%R 10.1634/theoncologist.2018-0084
%K Locally advanced or metastatic urothelial carcinoma
%K Bladder cancer
%K Platinumİ\containing chemotherapy
%K Atezolizumab
%K Programmed deathİ\ligand 1 antibody
%K Pembrolizumab
%K Programmed death receptorİ\1 antibody immunotherapy
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6459239/